Moscow, October, 28 2008
Quantum announce drug discovery collaboration with Children’s Cancer Institute Australia’s (CCIA). Under the terms of the agreement Quantum gets access to CCIA in-house disease target data. Quantum will contribute its technological breakthroughs and expertise in small molecule drug discovery to feed the portfolio of CCIA with new drug candidates. CCIA is to further develop the discovered inhibitors. The targets and financial terms were not disclosed.
About Quantum
Quantum is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
About CCIA
Children’s Cancer Institute Australia’s (CCIA) vision is to save the lives of all children with cancer and eliminate their suffering.Our mission is to be a leader in preventing cancer, to find new ways of curing cancer in children through world-class research, to ensure the best possible quality of life for these children and their families, to share the vision with others and to increase awareness, participation and funding.
More From fedichev
- q-hERG: QUANTUM’s innovative approach to hERG binding calculations is updated to v 2.0
- Quantum Pharmaceuticals collaborates with Fox Chase Cancer Center on discovery of new small molecules inhibitors in cancer area.
- Quantum Pharmaceuticals and Otechestvennye Lekarstva OJSC entered drug discovery collaboration.
Related posts:
- Quantum collaborates with Fox Chase Cancer Center on discovery of new small molecules inhibitors in cancer area.
- Quantum and Institute of Pulmonology entered COPD drug discovery collaboration.
- HIV-1 integrase drug discovery collaboration
- Quantum and Otechestvennye Lekarstva OJSC entered drug discovery collaboration.
- Quantum and MOLECMO Nanobiotechnologies announce collaboration.
